Moreover, studies conducted by our group and others have demonstrated that MEK inhibitors exhibit antitumor activity as single agents and in combination with other targeted therapeutics in preclinical models of CRC [56–59]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.